Y-mAbs Therapeutics Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Mike Rossi
Algemeen directeur
US$3.1m
Totale compensatie
Percentage CEO-salaris | 3.5% |
Dienstverband CEO | less than a year |
Eigendom CEO | n/a |
Management gemiddelde ambtstermijn | 3.6yrs |
Gemiddelde ambtstermijn bestuur | 7yrs |
Recente managementupdates
Recent updates
Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers
Oct 21Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%
Sep 12Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)
Aug 12We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
Jul 15Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%
Jun 02Y-mAbs: There's A Ceiling Here Somewhere
May 09We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
Mar 14Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry
Feb 17Y-mAbs Therapeutics: A Monoclonal Antibody Play
Jan 14We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate
Nov 13We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth
Jul 16Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts
May 13Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%
Apr 17Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely
Mar 22We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully
Dec 13Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically
Aug 13Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers
Jul 12Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers
May 30Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?
May 12Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$25m |
Mar 31 2024 | n/a | n/a | -US$22m |
Dec 31 2023 | US$3m | US$110k | -US$21m |
Compensatie versus markt: De totale vergoeding ($USD 3.11M ) Mike } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.24M ).
Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Mike te vergelijken met de prestaties van het bedrijf.
CEO
Mike Rossi (53 yo)
less than a year
Tenure
US$3,110,553
Compensatie
Mr. Michael Rossi, also known as Mike, serves as Chief Executive Officer, President & Director of Y-mAbs Therapeutics, Inc. since November 06, 2023. He has been Director at Nucleus RadioPharma, Inc. He had...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO, President & Director | less than a year | US$3.11m | geen gegevens | |
Founder | 9.6yrs | US$2.45m | 0.58% $ 3.8m | |
Senior VP & Chief Commercial Officer | 2.8yrs | US$887.28k | 0.0095% $ 62.7k | |
CFO & Treasurer | less than a year | geen gegevens | geen gegevens | |
Senior VP & COO | 7yrs | geen gegevens | 0.0021% $ 13.8k | |
Senior VP & CTO | 8.8yrs | geen gegevens | 0.12% $ 760.5k | |
Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
Senior VP & Chief Medical Officer | 4.4yrs | US$724.92k | 0.019% $ 125.1k | |
Chief Development Officer | less than a year | geen gegevens | geen gegevens |
3.6yrs
Gemiddelde duur
54.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van YMAB wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
CEO, President & Director | less than a year | US$3.11m | geen gegevens | |
Founder | 9.6yrs | US$2.45m | 0.58% $ 3.8m | |
Independent Chairman of the Board | 7yrs | US$184.31k | 0.063% $ 414.3k | |
Independent Director | 6.9yrs | US$180.56k | 0.0052% $ 34.4k | |
Director | less than a year | geen gegevens | 0% $ 0 | |
Independent Director | 9.2yrs | US$158.06k | 0.0052% $ 34.4k | |
Independent Director | 7yrs | US$158.06k | 0.0052% $ 34.4k | |
Independent Director | 4.4yrs | US$168.06k | 0.0052% $ 34.4k |
7.0yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van YMAB wordt beschouwd als ervaren (gemiddelde ambtstermijn 7 jaar).